GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Notes Receivable

Bright Minds Biosciences (XCNQ:DRUG) Notes Receivable : C$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Notes Receivable?

Bright Minds Biosciences's Notes Receivable for the quarter that ended in Dec. 2023 was C$0.00 Mil.


Bright Minds Biosciences Notes Receivable Historical Data

The historical data trend for Bright Minds Biosciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Notes Receivable Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Notes Receivable
- - - -

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bright Minds Biosciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Bright Minds Biosciences Notes Receivable Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences (XCNQ:DRUG) Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences (XCNQ:DRUG) Headlines

From GuruFocus